"Rituximab in Treatment of Chronic Spontaneous Urticaria"
نویسندگان
چکیده
Saira Zafar1*, Erin McGintee2, Alan Wolff1, Arthur Torre1 and Steven E Schutzer1 Author Affiliations 1Rutgers New Jersey School of Medicine, Allergy Immunology, USA 2Stony Brook Southampton Hospital, Received: February 07, 2022 | Published: 22, Corresponding author: Zafar, Rutgers Jersey, DOI: 10.26717/BJSTR.2022.42.006698
منابع مشابه
Treatment of Chronic Spontaneous Urticaria
Chronic spontaneous urticaria is defined as persistent symptoms of urticaria for 6 weeks or more. It is associated with autoimmunity in approximately 45 percent of patients. Therapy is often difficult however the initial approach should employ high-dose non-sedating antihistamines; 4-6 tablets/day may be necessary. It has been shown that the response to 4 tablets/day exceeds 3, and exceeds 2, w...
متن کاملAcupuncture in the treatment of chronic Urticaria
Background: Urticaria is very common and most of the current treatments are only partially successful. Objective: As the efficacy of acupuncture in the treatment of chronic urticaria has not been studied in Iran, we decided to do this study. Patients and Methods: In a randomized, controlled, double-blind clinical trial, 40 patients with chronic urticaria referred to skin clinics of Isfahan Univ...
متن کاملChronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations
The treatment of chronic spontaneous urticaria begins with antihistamines; however, the dose required typically exceeds that recommended for allergic rhinitis. Second-generation, relatively non-sedating H₁-receptor blockers are typically employed up to 4 times a day. First-generation antihistamines, such as hydroxyzine or diphenhydramine (Atarax or Benadryl), were employed similarly in the past...
متن کاملProfile of omalizumab in the treatment of chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is a disease with significant morbidity and relative prevalence that has important effects on the quality of life (QoL) of those who suffer from it. Omalizumab is a recombinant humanized anti-immunoglobulin E (IgE) antibody that binds to the Cε3 domain of the IgE heavy chain and prevents it from binding to its high-affinity receptor FcεRI. It has been largely...
متن کاملOmalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
BACKGROUND Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an anti-IgE monoclonal antibody [corrected] that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients. METHODS In this phase 3, multicenter, ran...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biomedical Journal of Scientific and Technical Research
سال: 2022
ISSN: ['2574-1241']
DOI: https://doi.org/10.26717/bjstr.2022.42.006698